What's happening
Writing a plain-English summary… Track this bill to get it by email.
Why it matters
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
Headline styles
Sponsors
No co-sponsors yet.
History
- Referred to higher education
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Requires written notification where a pharmacist is substituting a generic version of a drug product by one manufacturer for a generic version of a drug product by another manufacturer
In Assembly Committee · Higher Education · Sponsor Linda Rosenthal
Full text
The text isn't available here yet. Check nysenate.gov.
Sponsor's memo
Title of bill
An act to amend the education law, in relation to requiring written notification to patients where a pharmacist is substituting a generic version of a drug product by one manufacturer for a generic version of a drug product by another manufacturer
Purpose
This bill will mandate that patients be informed in writing when pharmacists substitute one version of a generic drug product by one manufacturer for another.
Summary of provisions
The bill would amend the Education Law by amending Section 6816-a to include a new subdivision 3. The new subdivision will mandate that a pharmacist inform a patient if he or she is substituting a generic version of a drug product by one manufacturer for a generic version of a drug product by another manufacturer.
Justification
Although the name "generic" suggests complete parity between prescription drugs, there can be considerable differences between different generic brands of the same medication. Regulations permit for variation in medication's inactive ingredients, including flavors, fillers and dyes. More importantly, generic drugs may vary in potency and can still be considered "bio-equivalent" while achieving blood serum level differences of 80-125%. A recent position paper released by the American Academy of Neurology argues that discrepancies of this magnitude can have serious medical implications for patients.
Certain manufacturers have also been subject to repeated products recalls, and this legislation would inform consumers of the generic manufacturer, giving them the ability to reach an informed decision and notifying them when a switch is made.
Legislative history
New bill.
Fiscal implications
None.
Effective date
This act shall take effect on the sixtieth day after it shall have become a law.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.